Search Results
Head and Neck Roundtable ASCO 2016 Common Side Effects of PD-1 Inhibitors
Dr. Weiss on Next Steps for Immunotherapy in Head and Neck Cancer
Where to go next with pembrolizumab and other anti-PD-1 therapies in head and neck cancer
Innovative approaches to the treatment of head and neck cancer
Head and Neck Cancer Treatment Update: Pembrolizumab, Nivolumab and PD-L1 Markers
Think About the Link® Congressional Briefing March 14th, 2016: Erich Sturgis, MD
Laura Chow, MD interprets the overall survival benefit with Opdivo in the CheckMate-141 study
Immuno-oncology Developments - Combinations and Use as First-Line Therapy #7
Cisplatin with Radiation, Toxicity Problems with the Standard Regimen
Understanding the Impact of Immunotherapy on Head and Neck Cancer
Patient Selection for Nivolumab in HNSCC
Reducing Risk of Cancer Recurrence through Exercise
